Cite

HARVARD Citation

    Hallek, M. et al. (2015). The HELIOS trial protocol: a Phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia. Future oncology. pp. 51-59. [Online]. 
  
Back to record